Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

| Data collection | In this study, we included genetic and phenotypic data from UK Biobank (UKB) and Boston Birth Cohort. The detailed information for each study is described in the methods section. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data analysis   | In this study, we performed various genetic analysis, including genome-wide association study, colocalization analysis, Mendelian randomization analysis, etc. The detailed information is described in the methods section. |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

UK Biobank data are available through the UK Biobank Access Management System https://www.ukbiobank.ac.uk/.
Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender
UK Biobank (UKB), a large-scale prospective cohort study with detailed phenotypic and genetic data on half a million participants aged between 40-69 years across the United Kingdom. Described in full in the methods section.

Population characteristics
UK Biobank (UKB), a large-scale prospective cohort study with detailed phenotypic and genetic data on half a million participants aged between 40-69 years across the United Kingdom. Described in full in the methods section.

Recruitment
Described in full in the methods section.

Ethics oversight
The UK Biobank has been reviewed and approved by local research ethics boards. All participants provided informed consent, and study procedures were performed in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/hr-reporting-summary-fig.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

- Sample size
  UK Biobank (UKB), a large-scale prospective cohort study with detailed phenotypic and genetic data on half a million participants aged between 40-69 years across the United Kingdom. Described in full in the methods section.

- Data exclusions
  Some samples were excluded based on genetic ancestry to ensure homogeneity. This is described in the methods.

- Replication
  We used Boston Birth Cohort and publicly available data to replicated the findings.

- Randomization
  Samples were from collected study cohorts and were not randomized.

- Blinding
  Samples were from collected study cohorts and were not blinding.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------|
| n/a | Involved in the study |
| ☒ Antibodies | ☐ ChiP-seq |
| ☒ Eukaryotic cell lines | ☐ Flow cytometry |
| ☒ Palaeontology and archaeology | ☐ MRI-based neuroimaging |
| ☒ Animals and other organisms | ☐ Clinical data |
| ☒ Clinical data | ☐ Dual use research of concern |